Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Grifols, S.A.
  6. Summary
    GRF   ES0171996087

GRIFOLS, S.A.

(GRF)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
09/17/2021 09/20/2021 09/21/2021 09/22/2021 09/23/2021 Date
21.82(c) 22.2(c) 22.29(c) 22.04(c) 22.15 Last
3 099 072 1 524 929 993 933 792 795 46 681 Volume
+5.77% +1.74% +0.41% -1.12% +0.50% Change
More quotes
Estimated financial data (e)
Sales 2021 5 296 M 6 205 M 6 205 M
Net income 2021 561 M 657 M 657 M
Net Debt 2021 6 013 M 7 045 M 7 045 M
P/E ratio 2021 26,4x
Yield 2021 1,42%
Sales 2022 5 749 M 6 736 M 6 736 M
Net income 2022 721 M 845 M 845 M
Net Debt 2022 5 861 M 6 867 M 6 867 M
P/E ratio 2022 20,6x
Yield 2022 1,78%
Capitalization 12 778 M 15 000 M 14 971 M
EV / Sales 2021 3,55x
EV / Sales 2022 3,24x
Nbr of Employees 23 431
Free-Float 79,7%
More Financials
Company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end... 
Sector
Pharmaceuticals
Calendar
11/10Earnings Release
More about the company
Ratings of Grifols, S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about GRIFOLS, S.A.
09/22European ADRs Climb Higher in Wednesday Trading
MT
09/22GRIFOLS S A : S&P Maintains Grifols' Negative Outlook Amid $2.34 Billion Acquisition Of Bi..
MT
09/20European ADRs Move Sharply Lower in Monday Trading
MT
09/20BIOTEST AG : Release according to Article 40, Section 1 of the WpHG [the German Securities..
DJ
09/17European Bourses Close in Red on Annual Inflation Data, Slowing Economic Growth
MT
09/17European ADRs Down Nearly 2% Friday as Mining, Steel Shares Drop
MT
09/17GLOBAL MARKETS LIVE : Ryanair, Ford, Apple, Alphabet, Gap...
09/17BIOTEST AG : Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for th..
DJ
09/17GRIFOLS S A : Form 6-K)
PU
09/17GRIFOLS S A : Further Expands Plasma Capabilities With $1.3 Billion Biotest Deal
MT
09/17GRIFOLS S A : to Acquire Controlling Stake in German Rival Biotest
MT
09/17European shares fall for third week in a row, miners worst hit
RE
09/17GRIFOLS S A : To Buy Majority Stake In Germany's Biotest For $1.3 Billion
MT
09/17GRIFOLS S A : Spain's Grifols to buy rival Biotest for up to $1.9 bln
RE
09/17GRIFOLS S A : announces its investment in Biotest
PU
More news
News in other languages on GRIFOLS, S.A.
09/22Les ADR européens grimpent dans les échanges de mercredi
09/22S&P maintient la perspective négative de Grifols après l'acquisition de Biotest pour 2,..
09/21GRIFOLS : Invest Securities salue l'acquisition de Biotest
09/20Les ADR européens en forte baisse dans les échanges de lundi
09/20BIOTEST AG : Veröffentlichung gemäß ž 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbrei..
More news
Analyst Recommendations on GRIFOLS, S.A.
More recommendations
Chart GRIFOLS, S.A.
Duration : Period :
Grifols, S.A. Technical Analysis Chart | GRF | ES0171996087 | MarketScreener
Technical analysis trends GRIFOLS, S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 22,04 €
Average target price 27,17 €
Spread / Average Target 23,3%
EPS Revisions
Managers and Directors
Raimon Grifols Roura Joint Chief Executive Officer & Executive Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
VÝctor Grifols Roura Non-Executive Chairman
Xavier Sueiras Gil Chief Information Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
GRIFOLS, S.A.-7.71%15 000
CSL LIMITED10.32%103 374
WUXI BIOLOGICS (CAYMAN) INC.18.19%66 169
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 198
BIOGEN INC.18.16%43 118
ALEXION PHARMACEUTICALS, INC.0.00%40 336